Mechanism of 17-beta-estradiol-induced Erk1/2 activation in breast cancer cells. A role for HER2 AND PKC-delta

J Biol Chem. 2002 Jun 21;277(25):22558-65. doi: 10.1074/jbc.M202351200. Epub 2002 Apr 17.

Abstract

Activation of mitogen-activated protein kinase (Erk/MAPK) is a critical signal transduction event for estrogen (E(2))-mediated cell proliferation. Recent studies from our group and others have shown that persistent activation of Erk plays a major role in cell migration and tumor progression. The signaling mechanism(s) responsible for persistent Erk activation are not fully characterized, however. In this study, we have shown that E(2) induces a slow but persistent activation of Erk in MCF-7 breast carcinoma cells. The E(2)-induced Erk activation is dependent on new protein synthesis, suggesting that E(2)-induced growth factors play a major role in Erk activation. When MCF-7 cells were treated with E(2) in the presence of an anti-HER-2 monoclonal antibody (herceptin), 60-70% of E(2)-induced Erk activation is blocked. In addition, when untreated MCF-7 cells were exposed to conditioned medium from E(2)-treated cells, Erk activity was significantly enhanced. Furthermore Erk activity was blocked by an antibody against HER-2 or by heregulin (HRG) depletion from the conditioned medium through immunoprecipitation. In contrast, epidermal growth factor receptor (Ab528) antibody only blocked 10-20% of E(2)-induced Erk activation, suggesting that E(2)-induced Erk activation is predominantly mediated through the secretion of HRG and activation of HER-2 by an autoctine/paracrine mechanism. Inhibition of PKC-delta-mediated signaling by a dominant negative mutant or the relatively specific PKC-delta inhibitor rottlerin blocked most of the E(2)-induced Erk activation but had no effect on TGF alpha-induced Erk activation. By contrast inhibition of Ras, by inhibition of farnesyl transferase (Ftase-1) or dominant negative (N17)-Ras, significantly inhibited both E(2)- and TGF alpha-induced Erk activation. This evaluation of downstream signaling revealed that E(2)-induced Erk activation is mediated by a HRG/HER-2/PKC-delta/Ras pathway that could be crucial for E(2)-dependent growth-promoting effects in early stages of tumor progression.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Blotting, Western
  • Breast Neoplasms / enzymology*
  • Cell Division
  • Cycloheximide / pharmacology
  • DNA, Complementary / metabolism
  • Disease Progression
  • Enzyme Activation
  • ErbB Receptors / metabolism
  • Estradiol / pharmacology*
  • Genes, Dominant
  • Humans
  • Isoenzymes / metabolism
  • Isoenzymes / physiology*
  • Mitogen-Activated Protein Kinase 1 / metabolism*
  • Mitogen-Activated Protein Kinase 3
  • Mitogen-Activated Protein Kinases / metabolism*
  • Models, Biological
  • Monomeric GTP-Binding Proteins / metabolism
  • Neuregulin-1 / metabolism
  • Precipitin Tests
  • Protein Binding
  • Protein Kinase C / metabolism
  • Protein Kinase C / physiology*
  • Protein Kinase C-delta
  • Protein Synthesis Inhibitors / pharmacology
  • Receptor, ErbB-2 / metabolism
  • Receptor, ErbB-2 / physiology*
  • Signal Transduction
  • Time Factors
  • Transfection
  • Transforming Growth Factor alpha / metabolism
  • Tumor Cells, Cultured

Substances

  • DNA, Complementary
  • Isoenzymes
  • Neuregulin-1
  • Protein Synthesis Inhibitors
  • Transforming Growth Factor alpha
  • Estradiol
  • Cycloheximide
  • ErbB Receptors
  • Receptor, ErbB-2
  • PRKCD protein, human
  • Protein Kinase C
  • Protein Kinase C-delta
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • Mitogen-Activated Protein Kinases
  • Monomeric GTP-Binding Proteins